Can a Stop-Smoking drug help Parkinson's patients stop falling?
NCT ID NCT06679374
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether varenicline (Chantix), a drug used to help people quit smoking, can reduce falls in people with Parkinson's disease. About 102 participants will take either varenicline or a placebo for one year. Researchers will measure changes in walking speed while multitasking and track the number of falls.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Varenicline (Chantix)
- What this could lead to
- If it works, this could point toward a treatment to reduce falls and improve walking safety in people with Parkinson's disease.
- What could go wrong
- This is a Phase 2 trial with only 102 participants, so results may not apply to everyone. Varenicline can cause side effects like nausea, sleep problems, or mood changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Planning ahead: could a simple program transform Parkinson's care?
- Sound waves vs. Parkinson's: can ultrasound calm tremors and stiffness?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can we outsmart Gaucher's hidden toll on lungs, bones, and brain?
- Could a brain disease change behavior years before diagnosis?